Serologicals homes in on SARS (severe acute respiratory syndrome):
This article was originally published in Clinica
Executive Summary
Serologicals' research division Chemicon International is to launch a qualitative nucleic acid test for detecting SARS (severe acute respiratory syndrome) in its early phase. The OligoDetect assay consists of a simple ELISA-based colorimetric procedure and a microplate reader. It can be used easily by laboratories that do not have costly real-time instrumentation to run assays, says the firm. Capable of producing a result in under three hours, the test will be available as an FDA listed analyte-specific reagent from Chemicon and its worldwide distributor network. Atlanta, Georgia based Serologicals recently announced plans to discontinue its therapeutic plasma business and to focus on its segments for cell culture supplements, research reagents and diagnostic antibodies.